Drug Approval | February 18, 2023
Themis gets DCGI approval of Remifentanil Hydrochloride 1mg/2mg injection for import and marketing
Themis will market this drug with the brand name REMITHEM.
Themis will market this drug with the brand name REMITHEM.
The respective product approval is based on Revlimid Capsules, 5mg, 10mg, 15mg, 25mg and 2.5mg, 20mg as a reference product
Technology and innovation play a pivotal role towards enhancing healthcare systems, increasing access to healthcare services, and reducing costs of therapies and consultations
The company is in the process of appointing the new Chief Financial Officer shortly and in the interim, Komal Gupta will continue as CFO
He is a Chartered Accountant with more than 19 years of extensive experience
It dwells on colocating 157 nursing colleges with medical colleges and eliminating sickle cell anaemia by 2047
The Survey highlighted that Indian pharmaceutical exports achieved a healthy growth of 24 per cent in FY21 and expressed hope that India’s domestic pharmaceutical market is estimated to grow to US $65 billion by 2024 from estimated US $41 billion in 2021
It will help upgrade the infrastructure and technologies of the country's biopharmaceuticals and in-vitro diagnostic industry
The centre has initiated next generation sequencing (NGS) as a tool for undertaking studies on genomic epidemiology of pathogens
Dr. Mandaviya and Dharmendra Pradhan dedicate Burns Centre at AIIMS; Lays foundation stone of Critical Care Hospital Building, and award 40 gold medals to meritorious students
Subscribe To Our Newsletter & Stay Updated
